دورية أكاديمية
أعرض في EDS

CRISPR-Cas9 base editors and their current role in human therapeutics.

التفاصيل البيبلوغرافية
العنوان: CRISPR-Cas9 base editors and their current role in human therapeutics.
المؤلفون: Lahr WS; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, USA., Sipe CJ; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, USA., Skeate JG; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, USA., Webber BR; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA., Moriarity BS; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota, USA; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: mori0164@umn.edu.
المصدر: Cytotherapy [Cytotherapy] 2023 Mar; Vol. 25 (3), pp. 270-276. Date of Electronic Publication: 2023 Jan 10.
نوع المنشور: Review; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE
أسماء مطبوعة: Publication: 2013- : London : Elsevier
Original Publication: Oxford, England : ISIS Medical Media, c1999-
مواضيع طبية MeSH: CRISPR-Cas Systems*/genetics , Gene Editing*, Humans ; Genetic Therapy ; DNA
مستخلص: Background: Consistent progress has been made to create more efficient and useful CRISPR-Cas9-based molecular toolsfor genomic modification.
Methods: This review focuses on recent articles that have employed base editors (BEs) for both clinical and research purposes.
Results: CRISPR-Cas9 BEs are a useful system because of their highefficiency and broad applicability to gene correction and disruption. In addition, base editing has beensuggested as a safer approach than other CRISPR-Cas9-based systems, as it limits double-strand breaksduring multiplex gene knockout and does not require a toxic DNA donor molecule for genetic correction.
Conclusion: As such, numerous industry and academic groups are currently developing base editing strategies withclinical applications in cancer immunotherapy and gene therapy, which this review will discuss, with a focuson current and future applications of in vivo BE delivery.
(Published by Elsevier Inc.)
References: Nat Genet. 2001 Mar;27(3):247-54. (PMID: 11242102)
Front Pediatr. 2021 Aug 13;9:710465. (PMID: 34485197)
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8. (PMID: 26582918)
Nat Biotechnol. 2018 Oct;36(9):843-846. (PMID: 29813047)
Mol Ther Nucleic Acids. 2015 Nov 17;4:e264. (PMID: 26575098)
Nat Biotechnol. 2015 Jan;33(1):73-80. (PMID: 25357182)
Adv Genet. 2014;88:13-36. (PMID: 25409602)
Cell Res. 2017 Jan;27(1):154-157. (PMID: 27910851)
Mol Ther. 2021 Apr 7;29(4):1602-1610. (PMID: 33359667)
Nat Med. 2020 Apr;26(4):535-541. (PMID: 32284612)
Genetics. 2011 Aug;188(4):773-82. (PMID: 21828278)
Curr Gene Ther. 2011 Feb;11(1):11-27. (PMID: 21182466)
Nat Commun. 2019 Nov 19;10(1):5222. (PMID: 31745080)
Nat Methods. 2017 Jul;14(7):710-712. (PMID: 28581493)
Mol Cell. 2016 Mar 17;61(6):886-94. (PMID: 26990991)
Nat Commun. 2019 Mar 08;10(1):1136. (PMID: 30850590)
Mol Ther. 2020 Jun 3;28(6):1389-1391. (PMID: 32428441)
Circ Res. 2020 Sep 25;127(8):1112-1114. (PMID: 32808882)
Nature. 2016 May 19;533(7603):420-4. (PMID: 27096365)
Cell. 2010 Jun 11;141(6):970-81. (PMID: 20550933)
Nature. 2021 Jul;595(7866):295-302. (PMID: 34079130)
Blood Cancer J. 2021 Apr 6;11(4):69. (PMID: 33824268)
Cell. 2008 Nov 28;135(5):907-18. (PMID: 19041753)
Nat Med. 2018 Jul;24(7):939-946. (PMID: 29892062)
Sci Adv. 2017 Aug 30;3(8):eaao4774. (PMID: 28875174)
Protein Cell. 2017 Nov;8(11):811-822. (PMID: 28942539)
Curr Opin Virol. 2016 Dec;21:75-80. (PMID: 27596608)
Nucleic Acids Res. 2011 Jul;39(12):e82. (PMID: 21493687)
Hum Gene Ther. 2010 Jun;21(6):704-12. (PMID: 20095819)
Nat Rev Drug Discov. 2005 Jul;4(7):581-93. (PMID: 16052241)
Nature. 2019 May;569(7757):560-564. (PMID: 31118521)
Mol Cell. 2012 Aug 24;47(4):497-510. (PMID: 22920291)
Science. 2020 Apr 17;368(6488):290-296. (PMID: 32217751)
Int J Mol Sci. 2022 Jul 29;23(15):. (PMID: 35955545)
Nat Biotechnol. 2018 Sep;36(8):765-771. (PMID: 30010673)
Cell. 2022 Jan 20;185(2):250-265.e16. (PMID: 35021064)
Mol Ther. 2020 Jun 3;28(6):1422-1431. (PMID: 32243835)
Cell. 2020 Jul 23;182(2):463-480.e30. (PMID: 32533916)
Mol Ther Methods Clin Dev. 2018 Jun 15;10:105-112. (PMID: 30073181)
Asian J Transfus Sci. 2020 Jul-Dec;14(2):185-186. (PMID: 33767547)
Science. 2018 Mar 23;359(6382):1361-1365. (PMID: 29567707)
PLoS Genet. 2021 Oct 11;17(10):e1009835. (PMID: 34634037)
Nat Commun. 2020 Apr 24;11(1):1979. (PMID: 32332735)
Mol Ther. 2022 Apr 6;30(4):1396-1406. (PMID: 35121111)
Nature. 2017 Nov 23;551(7681):464-471. (PMID: 29160308)
Cell. 2014 Feb 27;156(5):935-49. (PMID: 24529477)
BMC Genomics. 2018 Mar 21;19(1):212. (PMID: 29562890)
Nat Commun. 2017 Jun 06;8:15790. (PMID: 28585549)
Pediatrics. 1971 Dec;48(6):853-6. (PMID: 5166975)
Mol Ther. 2021 Feb 3;29(2):822-837. (PMID: 32949495)
Nat Biotechnol. 2020 Jul;38(7):883-891. (PMID: 32433547)
Chem Rev. 2009 Feb;109(2):259-302. (PMID: 19053809)
Nat Biotechnol. 2015 Feb;33(2):179-86. (PMID: 25503383)
Nature. 2021 Jan;589(7843):608-614. (PMID: 33408413)
Nat Genet. 2014 Mar;46(3):310-5. (PMID: 24487276)
Nat Rev Mater. 2019 Nov;4:726-737. (PMID: 34094589)
Nat Biomed Eng. 2020 Jan;4(1):97-110. (PMID: 31937940)
Nat Med. 2018 Jul;24(7):927-930. (PMID: 29892067)
Protein Sci. 2014 Dec;23(12):1650-66. (PMID: 25234433)
Front Physiol. 2020 May 20;11:435. (PMID: 32508672)
Nat Commun. 2021 Apr 23;12(1):2437. (PMID: 33893286)
Cell Stem Cell. 2020 Apr 2;26(4):503-510.e7. (PMID: 32084388)
Science. 2012 Aug 17;337(6096):816-21. (PMID: 22745249)
Nature. 2021 May;593(7859):429-434. (PMID: 34012082)
Cell Prolif. 2020 May;53(5):e12820. (PMID: 32350961)
Nat Biotechnol. 2013 Sep;31(9):822-6. (PMID: 23792628)
Nat Biotechnol. 2020 Jul;38(7):892-900. (PMID: 32284586)
Nat Med. 2019 May;25(5):776-783. (PMID: 30911135)
Blood Adv. 2021 Feb 23;5(4):1122-1135. (PMID: 33620431)
Nature. 2018 Aug;560(7717):E8-E9. (PMID: 30089922)
Hum Mol Genet. 2015 Oct 15;24(R1):R102-10. (PMID: 26152199)
Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6. (PMID: 32531207)
Front Immunol. 2020 Nov 11;11:583716. (PMID: 33262761)
Nat Genet. 2021 Jun;53(6):895-905. (PMID: 33846636)
Nat Rev Genet. 2011 May;12(5):316-28. (PMID: 21468099)
Nat Rev Drug Discov. 2022 Aug;21(8):545-547. (PMID: 35831515)
معلومات مُعتمدة: R01 AI161017 United States AI NIAID NIH HHS; T32 HL007062 United States HL NHLBI NIH HHS; R21 CA237789 United States CA NCI NIH HHS; P50 CA136393 United States CA NCI NIH HHS; R21 AI163731 United States AI NIAID NIH HHS; P01 CA254849 United States CA NCI NIH HHS; R01 AI146009 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: base editor; cancer immunotherapy; gene therapy; hematopoietic stem cell; multiplex gene editing; sickle cell
المشرفين على المادة: 10191-18-1 (BES)
9007-49-2 (DNA)
تواريخ الأحداث: Date Created: 20230112 Date Completed: 20230207 Latest Revision: 20240617
رمز التحديث: 20240617
مُعرف محوري في PubMed: PMC10887149
DOI: 10.1016/j.jcyt.2022.11.013
PMID: 36635153
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-2566
DOI:10.1016/j.jcyt.2022.11.013